Modelling the cost-effectiveness of essential and advanced critical care for COVID-19 patients in Kenya

Angela Kairu^{1*}, Vincent Were¹, Lynda Isaaka², Ambrose Agweyu², Samuel Aketch², Edwine Barasa^{1,3}

¹Health Economics Research Unit, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya

² Health Services Unit, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya

³ Center for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

*Corresponding Author: Angela Kairu, Health Economics Research Unit, KEMRI Wellcome Trust Research Programme, P.O.BOX 43640-00100, 197 Lenana Place, Off Lenana Road, Nairobi, Kenya,
Email: akairu@kemri-wellcome.org

ABSTRACT

Background: Case management of symptomatic COVID-19 patients is a key health system intervention. The Kenyan government embarked to fill capacity gaps in essential and advanced critical care needed for the management of severe and critical COVID-19. However, given scarce resources, gaps in both essential and advanced critical care persist. This study assessed the cost-effectiveness of investments in essential and advanced critical care to inform the prioritization of investment decisions.

Methods: We employed a decision tree model to assess the incremental cost-effectiveness of investment in essential care (EC) and investment in both essential and advanced critical care (EC+ACC) compared to current health care provision capacity (status quo) for COVID-19 patients in Kenya. We used a health system perspective, and an inpatient care episode time horizon. Cost data was obtained from primary empirical analysis while outcomes data was obtained from epidemiological model estimates. We used univariate and probabilistic sensitivity analysis (PSA) to assess the robustness of the results.

Results: The status quo option is more costly and less effective compared to investment in essential care and is thus dominated by the later. The incremental cost effectiveness ratio (ICER) of investment in essential and advanced critical care (EC+ACC) was US \$1,378.21 per DALY averted and hence not a cost-effective strategy when compared to Kenya's cost-effectiveness threshold (USD 908).

Conclusion: When the criterion of cost-effectiveness is considered, and within the context of resource scarcity, Kenya will achieve better value for money if it prioritizes investments in essential care before investments in advanced critical care. This information on cost-effectiveness will however need to be considered as part of a multi-criteria decision-making framework that uses a range of criteria that reflect societal values of the Kenyan society.

Keywords: COVID-19, cost-effectiveness, essential care, advanced critical care, Kenya

Key questions

What is already known?

- The COVID-19 pandemic is responsible for substantial health effects in low- and middle-income countries
- The case management of COVID-19 is one of the key control interventions deployed by country health systems.
- Similar to other low- and middle-income countries, Kenya had substantial gaps in both essential and advanced critical care at the beginning of the pandemic.

What are the new findings?

- Provision of essential care and advanced critical care for COVID-19 at the current health system capacity (status quo) was costly and the least effective strategy.
- Investment in both essential care and advanced critical care for COVID-19 is not cost-effective in Kenya when compared to investment in essential care.

What do the new findings imply?

- Prioritizing investments in filling capacity gaps in essential care before investing in filling capacity gaps in advanced critical care for COVID-19 is more cost-effective in Kenya
- These findings are intended to inform the sequencing of investments in case management rather than the selection of either strategy, within a context of substantial resource constraint, and capacity gaps in both essential and advanced critical care or COVID-19
- Kenya will need to consider these findings on cost-effectiveness within a multi-criteria decision-making framework that use a range of criteria that reflect societal values.

INTRODUCTION

The new coronavirus disease 2019 (COVID-19) has spread to nearly all countries and territories globally, with devastating impacts (1). As at 20th May 2021, 164.9 million cases of SARS-CoV-2 infections have been recorded resulting in 3.4 million deaths globally (2). In Kenya, 166,382 infections and 3,035 deaths from COVID-19 have been recorded as of 20th May 2021 (2). Beyond direct health impacts, the COVID-19 pandemic is responsible for substantial indirect health effects that include the disruption of the delivery and access of routine health services. It is also responsible for negative socio-economic impacts that include a slow-down of the global economy, increase in unemployment, impoverishment, disruption of schooling and threatening of food security, among others (3).

The case management of COVID-19 is one of the key control interventions deployed by country health systems. COVID-19 is a highly contagious infectious disease transmitted by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily via exposure to respiratory droplets (1). Clinically, COVID-19 presents as either of four severities namely 1) asymptomatic, 2) Mild/Moderate, 3) Severe, and 4) Critical COVID-19 (4, 5). In Kenya, case management guidelines recommend asymptomatic and mild/moderate COVID-19 be managed at home (home based care), while patients with severe and critical COVID-19 are provided institutional care in hospitals (6, 7). Patients with severe COVID-19 are typically managed in general hospital wards, and receive essential care that may include supplemental oxygen support (1), whereas patients with critical COVID-19 are managed in intensive care units (ICUs) and provided with advanced critical care such as mechanical ventilation, management of complications like respiratory failure, acute respiratory distress syndrome (ARDS), thromboembolism, sepsis and septic shock, and multi-organ failure such as cardiac and acute kidney injury, provided in intensive care unit (ICU) (1, 8, 9).

Like other low- and middle-income countries (LMICs), Kenya had substantial gaps in both essential and advanced critical care at the beginning of the pandemic. For instance, it is estimated that only 58% of hospital beds had access to medical oxygen at the start of the pandemic (10). Further, only 16% of healthcare facilities in Kenya were able to monitor oxygen saturation and therapy through pulse oximetry, and the mean availability of tracer items for emergency breathing interventions (pulse oximeters, micronebulizer, beclomethasone and salbutamol inhalers, oxygen with tubing, flowmeter, and humidifier, resuscitation bags, intubation devices with connecting tube, chest tubes with insertion sets, and CPAP equipment) was only 13% (10).

With regard to advanced critical care, Kenya had only 540 ICU beds for a population of nearly 50 million, with only 22% of the population living within 2 hours of a facility with an ICU (10).

Against this backdrop, the Kenyan government set out to invest in filling capacity gaps in both essential care and advanced critical care for COVID-19. However, because of resource constraints, gaps in both essential and advanced care persist one year into the pandemic (11). This has triggered discussions on the prioritization of investments when resources are scarce. If, as it is evident, the Kenyan government is unable to fill capacity gaps in both essential and advanced critical care, where should they start? In this paper, we use carry out an economic evaluation to inform this decision. Specifically, we compare the cost-effectiveness of investments in essential care and investments in advanced care in addition to essential care to the current health care provision capacity (status quo) for the management of symptomatic COVID-19 patients with severe and critical disease in Kenya.

METHODS

Study design

A decision tree analysis model in Tree Age Pro Healthcare 2020 was developed to evaluate the cost-effectiveness of investments in essential and advanced critical care for the management of COVID-19 patients in Kenya from a health systems perspective. The model followed a cohort of 2,288 individuals, representative of all individuals hospitalized for COVID-19 illness (until 30th January 2021) through two treatment pathways, estimating costs and health gains. In both treatment pathways, the COVID-19 patients were diagnosed as either having severe or critical illness depending on the severity of symptoms as defined by the Kenya ministry of health COVID-19 case management guidelines (6). A diagnosis was followed by treatment of severe patients in a general ward and critical patients in the intensive care unit (ICU). A time horizon of a patient care episode chosen.

Model structure

Three different treatment strategies are compared (Figure 1). Strategy one is defined as investment in filling essential care (EC) gaps broadly comprising of supplementary oxygen therapy (when needed), administration of empiric antimicrobials, monitoring of vital signs and laboratory tests. Strategy two is defined as investment in advanced critical care in addition to essential care (EC +ACC). Advanced critical care encompasses management of patients in an intensive care unit, advanced oxygen/ventilatory support, conservative fluid management,

advanced organ monitoring and support, empiric antimicrobials, and management of any complications (6). Strategy three is the baseline defined as status quo comprising of provision of EC and ACC within the current health system capacity. Appendix 1 provides a detailed description of what is included in each intervention, which were defined based on expert consensus and the clinical guidelines implemented (1, 6).

The study population is hospitalized COVID-19 patients admitted between March 2020 to January 2021. The model assumes, in line with Kenya COVID-19 case management guidelines, that only patients with severe and critical disease are admitted in hospitals for inpatient care (6). Severe cases present with the following symptoms: fever or suspected respiratory infection, plus one of respiratory rate >30 breaths/min, severe respiratory distress, or SpO₂ <93% (6). Critical cases are those who meet any of the following criteria: respiratory failure requiring mechanical ventilation, shock, and other organ failure requiring ICU care (6). All individuals completed the pathway when they were either recovered or dead. Data on the effectiveness of both comparators was obtained

from current literature, and where unavailable assumptions were based on expert opinion. However, these data sources were limited by the regions/areas studied as the extent of disease outcomes varied globally. Key model input parameters are shown in Table 1. In the cohort, COVID-19 patients were characterized as: (1) severe, and (2) critical. These proportions were sourced from current literature (12-14).

Table 1: Key cost-effectiveness model parameters

Parameter	Value (Lb; Ub)	Source
Population		
Number of patients with severe or critical COVID-19 requiring hospitalization in a year	20,836 (16,668; 25,003)	(15)
Proportion of hospitalized patients with severe COVID-19	0.86	(14)
Proportion of hospitalized patients with critical COVID-19	0.14	(14)
Proportion of severe COVID-19 that progress to critical (<i>if essential critical care is provided</i>)	0.0068	(16)
Proportion of severe COVID-19 that progress to critical (<i>if essential critical care is NOT provided</i>)	1	Author assumption
Proportion of severe COVID-19 that progresses to recovery (<i>if essential critical care is provided</i>)	0.99	(16)
Proportion of severe COVID-19 that progresses to recovery (<i>if essential critical care is NOT provided</i>)	0	Author assumption
Proportion of critical COVID-19 that progresses to recovery (<i>if advanced critical care is provided</i>)	0.396	(17)
Proportion of critical COVID-19 that progresses to recovery (<i>if advanced critical care is NOT provided</i>)	0	Author assumption
Health system capacity		
Proportion of baseline capacity for essential care	0.58	(10)

Proportion of baseline capacity for advanced critical care	0.22	(10)
Utilization		
Length of hospital stay critical COVID-19 patients (days)	7 (4; 10)	(17)
Length of hospital stay for severe COVID-19 patients (days)	6 (3; 9)	(18)
Mortality rates		
Proportion of critical COVID-19 that progresses to death (<i>if advanced critical care is provided</i>)	0.604	(17)
Proportion of critical COVID-19 that progresses to death (<i>if advanced critical care is NOT provided</i>)	1	Author assumption
DALYs		
Disability weight for critical care episode	0.655 (0.579; 0.727)	(19)
Disability weight for severe care episode	0.133 (0.088; 0.191)	(20)
Average age at death	55.5	(13)
Life expectancy	66.34	(21)
Unit costs		
Cost (USD) for critical care episode	599.91	(22)
Cost (USD) for severe care episode	124.53	(22)
Other		
Cost-effectiveness threshold per DALY averted	0.5 times country's GDP per capita (USD 1,816.5)	(23, 24)

Abbreviations: Lb, Lower bound; Ub, Upper bound; DALYs, Disability adjusted life years; USD, United States Dollar

Costing methods

An ingredients-based costing methodology was used to estimate unit costs of COVID-19 case management. The health system costs considered were associated with COVID-19 case management in hospitals (accommodation and overheads, staff, pharmaceuticals, non-pharmaceutical, personal protective equipment (PPEs), oxygen therapy, ICU equipment, COVID-

19 test, other laboratory tests, and radiology tests). Details of the costing and results are reported elsewhere (22).

Effectiveness and cost-effectiveness measurement

The model's primary outcome measure is the cost per disability adjusted life years (DALYs) averted. DALYs were calculated as the sum of years of life lost (YLL) and years of life with disability (YLD). We used standard methods to compute DALYs (25). DALYs were calculated using a discount rate of 3%, age weighting, Kenya's life expectancy of 66.34 (21), and assumed duration of illness of 12 days. The applied disability weight for severe respiratory infection was 0.133 (0.088-0.190, 95% CI) from the global disease burden (GDB) study 2013 (20) for severe COVID-19 disease, and the disability weight of 0.655 (0.579- 0.727) for ICU admission (19) for critical COVID-19 disease.

The incremental cost-effectiveness ratio (ICER) was the measure of cost-effectiveness calculated as the net change in total costs and DALYs averted between providing essential services compared to providing critical care for COVID-19 cases.

$ICER = \frac{(C_{ec} - C_{cc})}{(DALYs_{ec} - DALYs_{cc})}$ where the C_{ec} is the total cost of essential care for severe cases and C_{cc} is the total cost of critical care

The ICER was compared to the Kenya cost-effectiveness threshold estimated by Woods and colleagues (26) (ref) and Ochalek and colleagues (27) which translated to 50% of the country's GDP per capita (23).

Dealing with uncertainty

A one-way sensitivity analysis was conducted across all parameters to assess the effect of changes on the ICER. A 20 % increase or decrease was implemented for the parameters. However, where possible ranges for sensitivity analysis were based on upper and lower confidence intervals or interquartile ranges found within the systematic literature review. A probabilistic sensitivity analysis (Monte Carlo simulation) was performed to explore the effect of uncertainty across our model parameters. The key parameters included the per day costs for severe and critical patients, DALYs, length of stay, and the transition probabilities with defined distributions

(Appendix 2). The analysis randomly sampled each parameter in our model simultaneously from their probability distribution and repeated this 1,000 times to generate confidence intervals around our estimates of cost per DALY averted. The confidence intervals or variation of parameters and the effect on the cost effectiveness were also evaluated.

Finally, threshold analysis was run to estimate the percentage change in parameters that would render essential care and advanced critical care cost-effective using the CET as the cut-off for this determination.

RESULTS

Table 2 shows the costs, DALYs and the incremental cost-effectiveness ratio (ICER) associated with the three analysis options. The findings show that investing to fill capacity gaps in both essential care and advanced critical care is the most costly option, followed by the status quo option. Investment to fill gaps in essential care is the least costly option. Further, investments to fill capacity gaps in both essential care and advanced critical care is the most effective option (averts the most DALYs) while status quo option is the least effective option (averts the least DALYs). The status quo option is thus dominated by investment in essential care since it is both more costly and less effective than the latter. The incremental cost effectiveness ratio (ICER) of investment in essential and advanced critical care (EC+ACC) compared to investment in essential care (EC) is US \$1,378.21 per DALY averted. This is higher than the cost-effectiveness threshold for Kenya (USD 908), revealing that it is not cost-effective to prioritize the investment in advanced critical care.

Table 2: Cost-effectiveness results (USD 2020)

Strategy	Total costs (USD) (95% CI)	Total DALYs (95% CI)	Cost per DALY averted (USD)	Incremental cost per DALY averted (USD)
Essential care	16,197,611.92 (15,710,057.87; 16,438,588.93)	22,508.76 (22,232.71; 24,809.92)	719.61	
Status quo	17,474,037.20 (17,116,393.72; 17,728,192.34)	77,621.36 (74,977.46; 86,558.08)	225.11	-23.16

Essential care and advanced critical care	26,156,638.28 (25,594,910.55; 26,468,628.66)	15,282.71 (15,027.06; 16,817.24)	1711.52	1,378.21
--	--	--	---------	----------

Abbreviations: USD, United States Dollar

Sensitivity analysis

The univariate sensitivity analyses results are presented in the tornado diagram (Figure 2a) which summarizes the results for the four main parameters that had the largest effect on the ICER. These are: 1) probability of critical COVID-19 patients to progress to death (advanced critical care is provided) (lower mortality improves cost effectiveness); 2) length of stay for critical COVID-19 patients (shorter length of stay improves cost effectiveness); 3) the cost per day for advanced critical care (less costly improves cost effectiveness); 4) years of life lost (if more lost life years can be averted, essential care and advanced critical care becomes more cost effective).

These results indicate that if EC + ACC strategy was less costly (by unit cost reduction or the length of stay) or more effective (through targeting patients with more years of life to lose or reduced mortality), then this strategy would be more likely to be a cost-effective use of resources.

Figure 2a: Tornado diagram of Univariate sensitivity analysis of the parameters affecting the ICER.

Figure 2b: Tornado diagram of Univariate sensitivity analysis of the parameters affecting the ICER.

Figure 2b summarizes the results for the main parameters that had the largest effect on the ICER comparing status quo to investment in essential care. These are: 1) length of stay for critical COVID-19 patients; 2) length of stay for severe COVID-19 patients (both of which shorter length of stay improves cost effectiveness); 3) the cost per day for essential care (less costly improves cost effectiveness); 4) probability of severe COVID-19 patients to progress to recovery (current health system capacity) (higher recovery rates improves cost effectiveness).

These results indicate that if status quo strategy was less costly (by unit cost reduction or the length of stay) or more effective (through less patients progressing to critical disease or more severe COVID 19 patients recovering), then this strategy would be more likely to be a cost-effective use of resources.

Figures 3(a- c) outline findings of the probabilistic sensitivity analysis (PSA). The region with green dots below the WTP line shows all the points that are cost effective for the EC + ACC strategy. The findings show that at a cost-effectiveness threshold of USD 908.25, the probability of EC+ACC being the more cost-effective strategy is 22%.

The findings show that at a cost-effectiveness threshold of USD 908.25, the probability of status quo being the more cost-effective strategy is 2.7% when compared to essential care (figure 3b), and a probability of 10.8% of being the more cost-effective when compared EC + AC strategy (figure 3c).

DISCUSSION

This study presents a cost-effectiveness analysis of investment strategies to fill gaps in Kenya's health system capacity to provide case management for hospitalized COVID-19 patients. Specifically, we compare decisions to prioritize investments to fill existing gaps in essential care versus prioritizing to fill gaps in critical care in addition to essential care for COVID-19 patients. Our findings show that it is more cost-effective to prioritize (i.e. start with) investments to fill gaps in essential care rather than fill gaps in advanced critical care in addition to essential care. We offer several reflections on these findings.

The first, what explains this finding? The status quo option is both less effective and more costly. While it is intuitive that the status quo option is less effective, the finding that it is more costly needs some explanation. Under the status quo option, a large proportion of patients that need essential critical care miss it, and hence transition to critical care, which is more costly. Despite investment in advanced critical care in addition to essential care averting more DALYs compared to investments in essential care alone, it is substantially more expensive with cost per DALY averted being more than 2 times that of essential care. Other than the obvious high cost of advanced critical care, the proportion of hospitalized COVID-19 patients that need critical care (14%) is substantially lower than the proportion of patients that need essential care (86%) (14). Further, outcomes for advanced critical care are poor with only 39.6% recovering (17). These factors combine to make an investment in critical care in addition to essential care not cost effective. These findings mirror a similar analysis carried out in South Africa that found purchasing additional ICU care during COVID-19 surges not cost-effective (28).

Second, how should these findings be interpreted? We do not take these results to mean that Kenya should not invest in advanced critical care. Advanced critical care is evidently a vital intervention in the management of COVID-19 disease as evidenced in this analysis where it averts additional DALYs when combined with essential care, and may also have beneficial effects on the clinical management of other common conditions. However, within a context of a) substantial gaps in both essential care capacity and advanced critical care capacity and b) severe resource scarcity, what intervention should the Kenyan health sector prioritize? In other words, where should the Kenyan government start plugging the gaps? One option is to prioritize both, which within a budget constraint implies that both essential and advanced critical care will remain sub-optimal. This is indeed what we have observed in Kenya, with challenges in availability of essential care that includes oxygen and critical care persisting one year since the onset of the

pandemic despite arguably a low pandemic case burden compared to for instance countries in Europe and the US (2). Our findings show that it is more cost-effective to start by prioritizing investments in plugging gaps in essential care before investing in plugging gaps in advanced care. These findings are therefore intended to inform the sequencing of investments in case management rather than the selection of either of essential or advanced critical care. Sub-optimal investment in both essential and critical care does not optimize health outcomes within a given budget.

Third, while the findings of this cost-effectiveness analysis are intended to inform priority setting for COVID-19 investments, they are to be considered within a multi-criteria decision-making framework that reflect societal values. Our study findings provide quantitative evidence to inform such as multi-criteria priority setting framework. While priority setting criteria that are based on “rule of rescue” might favour investments in both essential and advanced critical care, this is likely have high opportunity costs. A utilitarian consideration that aims to benefit the most people will favour the prioritization of essential care.

A key limitation to our analysis is the scarcity of local data to parametrize the model. There is scant information on the clinical presentation, management, and outcomes of COVID-19 patients in Africa. We have however benefited from good quality data on COVID-19 surveillance in Kenya that has bridged this data gap. This notwithstanding, we have used assumptions and estimates from other settings for some of the parameters. While this may affect the validity of the findings for the Kenyan setting, the sensitivity analysis reveals that the data are largely robust to variations in these parameters. Second, this analysis considers COVID-19 as an acute condition although there is emerging evidence of long-term effects (29-31) and this has implications on the computation of DALYs. However, the information on long-term effects is still evolving.

This study contributes to the growing body of literature on health economics analysis of COVID-19. Within the context of resource scarcity, Kenya will achieve better value for money if it prioritizes investments in essential care before investments in advanced critical care. This information on cost-effectiveness will however need to consider alongside other priority setting considerations that are informed by the values of the Kenyan society.

Acknowledgements We acknowledge the POETIC project team for their expertise on Essential Emergency and Critical Care (EECC) and contribution to the intervention definitions.

Contributors EB conceptualised the study. EB, AK, VW and SA collected data. AK, VW and EB analysed the data. AK wrote the first draft of the manuscript. All authors contributed to subsequent revisions of the manuscript.

Funding This manuscript is published with the permission of the director of KEMRI. The work is funded by the International Decision Support Initiative (IDSi) Additional funds from a Wellcome Trust core grant (#092654) supported this study.

Disclaimer The funders had no role in study design, data analysis, decision to publish, drafting or submission of the manuscript. The views expressed in the paper are those of the authors and not of the organisations they represent.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This is a modelling study that relied on data from published and publicly available papers to parametrize the model

Patient and public involvement Not applicable to involve patients or the public in the design, or conduct, or reporting, or dissemination plans of our research

Provenance and peer review Not commissioned, externally peer reviewed.

Data availability statement All data relevant to the study are included in the article and are available in publicly accessible published papers. The links to the studies that contain the data are provided in the supplementary file

Footnotes

Twitter: Angela Kairu @angiekairu and Edwine Barasa @edwinebarasa

REFERENCES

1. WHO. COVID-19 Clinical Management, Living Guidance, 25 January 2021. Geneva: World Health Organization; 2021. Report No.: WHO/2019-nCoV/clinical/2021.1.
2. University JH. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) 2020 [Available from: <https://coronavirus.jhu.edu/map.html>].
3. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. *International journal of surgery*. 2020;78:185-93.
4. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. *New England journal of medicine*. 2020;382(18):1708-20.
5. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *Jama*. 2020;323(16):1574-81.
6. MOH. Interim guidelines on management of COVID-19 in Kenya [Internet]. Nairobi;2020.
7. MOH. Home-based isolation and care guidelines for patients with COVID-19 [Internet]. Nairobi, 2020.
8. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. *Journal of Medical Virology*. 2020.
9. Phua J, Weng L, Ling L, Egi M, Lim C-M, Divatia JV, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. *The Lancet Respiratory Medicine*. 2020;8(5):506-17.
10. Barasa EW, Ouma PO, Okiro EA. Assessing the hospital surge capacity of the Kenyan health system in the face of the COVID-19 pandemic. *PLoS One*. 2020;15(7):e0236308.
11. Barasa E, Kazungu J, Orangi S, Kabia E, Ogero M, Kasera K. Assessing the Indirect Health Effects of the COVID-19 Pandemic in Kenya. *CGD Work Pap*. 2021;570.
12. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *Jama*. 2020;323(13):1239-42.
13. Ombajo LA, Mutono N, Sudi P, Mutua M, Sood M, Ali Loo AM, et al. EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF COVID-19 PATIENTS IN KENYA. *medRxiv*. 2020:2020.11.09.20228106.
14. Nachega JB, Ishoso DK, Otokoye JO, Hermans MP, Machekano RN, Sam-Agudu NA, et al. Clinical characteristics and outcomes of patients hospitalized for COVID-19 in Africa: Early insights from the Democratic Republic of the Congo. *The American journal of tropical medicine and hygiene*. 2020;103(6):2419-28.
15. Brand SP, Ojal J, Aziza R, Were V, Okiro E, Kombe I, et al. COVID-19 Transmission Dynamics Underlying Epidemic Waves in Kenya. *medRxiv*. 2021.
16. Liu D, Cui P, Zeng S, Wang S, Feng X, Xu S, et al. Risk factors for developing into critical COVID-19 patients in Wuhan, China: a multicenter, retrospective, cohort study. *EClinicalMedicine*. 2020;25:100471.
17. Elhadi M, Alsoufi A, Abusalama A, Alkaseek A, Abdeewi S, Yahya M, et al. Epidemiology, outcomes, and utilization of intensive care unit resources for critically ill COVID-19 patients in Libya: A prospective multi-center cohort study. *Plos one*. 2021;16(4):e0251085.
18. Agweyu A. IL, Aman R., Kagucia E., Mwangangi M., Kasera K., Ng'ang'a W. Surveillance and epidemiologic evaluation of COVID-19 in Kenya (SEECK). 2020.
19. Haagsma JA, De Noordhout CM, Polinder S, Vos T, Havelaar AH, Cassini A, et al. Assessing disability weights based on the responses of 30,660 people from four European countries. *Population health metrics*. 2015;13(1):1-15.

20. Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH, et al. Disability weights for the Global Burden of Disease 2013 study. *The Lancet Global Health*. 2015;3(11):e712-e23.
21. Bank W. World Development Indicators, Life Expectancy at The World Bank Group 2018 [cited 2021 6 April]. Available from: <https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=KE>.
22. Barasa E, Kairu A, Maritim M, Were V, Akech S, Mwangangi M. Examining unit costs for COVID-19 case management in Kenya. *BMJ global health*. 2021;6(4):e004159.
23. Chi Y-L, Blecher M, Chalkidou K, Culyer A, Claxton K, Edoka I, et al. What next after GDP-based cost-effectiveness thresholds? *Gates Open Research*. 2020;4(176):176.
24. Bank W. National Accounts, GDP per capita at The World Bank Group 2019 [cited 2021 6 April]. Available from: <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=KE>
25. Rushby JF, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. *Health policy and planning*. 2001;16(3):326-31.
26. Woods B, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. *Value in Health*. 2016;19:929-35.
27. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. *BMJ Global Health*. 2018;3(e000964).
28. Cleary SM, Wilkinson T, Tchuem CT, Docrat S, Solanki G. Cost-effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa. *BMC health services research*. 2021;21(1):1-10.
29. Yelin D, Wirtheim E, Vetter P, Kalil AC, Bruchfeld J, Runold M, et al. Long-term consequences of COVID-19: research needs. *The Lancet Infectious Diseases*. 2020;20(10):1115-7.
30. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet*. 2021;397(10270):220-32.
31. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. *Jama*. 2020;324(6):603-5.

APPENDICES

Appendix 1: Description of essential care and advanced critical care

Essential care	Advanced critical care
<ul style="list-style-type: none"> • Supplementary oxygen therapy (nasal cannula, Venturi mask, face mask with reservoir bag) • Conservative fluid management (when necessary) • Regular monitoring of vital signs (including pulse oximetry) • Medication <ul style="list-style-type: none"> - Empiric antimicrobials - Administration of corticosteroids • Radiology test (chest radiograph) • Laboratory tests (SARS-CoV-2 RT-PCR test, full haemogram, urea electrolytes & creatinine (UECs), Aminotransferase alanine (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Lactate dehydrogenase (LD), random blood sugar, C-reactive protein) 	<ul style="list-style-type: none"> • Advanced oxygen/ventilatory support (mechanical ventilation) • Conservative fluid management • Cardiac and respiratory monitoring • Parenteral nutrition (when indicated) • Medication <ul style="list-style-type: none"> - Empiric antimicrobials - Administration of corticosteroids • Urine output monitoring • Radiology test (CT scan (when indicated), chest radiograph) • Laboratory tests (done routinely) <ul style="list-style-type: none"> - Biochemistry (SARS-CoV-2 RT-PCR test, full haemogram, urea electrolytes & creatinine (UECs), liver function tests, random blood sugar, D-dimers, ferritin levels, C-reactive protein, blood gas analysis) - Microbiology (blood culture, tracheal aspirate culture) • Prevention of complications <ul style="list-style-type: none"> - Pharmacological prophylaxis (anticoagulants) - Regular repositioning of patients • Management of complications <ul style="list-style-type: none"> - Sepsis and septic shock - Antimicrobial therapy, fluid management, administration of vasopressors - Administration of blood and blood products (when indicated) • Routine nursing care (nurse: patient ratio 1:1) • Rehabilitation (physiotherapy)

Appendix 2: Defined distributions for model parameters

Model parameters	Distribution
Total number and proportion of hospitalized patients	Normal
Transition probabilities	Beta
Costs	Gamma
Length of stay	Normal
DALYs	Lognormal